New stock news | Hansai Aitai Hong Kong IPO prospectus invalid

Halsun Aitai Biomedical Technology (Wuhan) Co., Ltd-B (referred to as Halsun Aitai) submitted its Hong Kong IPO prospectus on June 2nd, which expired on December 2nd, six months later, with ICBC International as its exclusive sponsor. According to the prospectus, Halsun Aitai is an innovative biotechnology company with expertise in structural biology, translational medicine, and clinical development. Since 2016, the company has been building an innovative pipeline, including one core product and nine other candidate products, namely (i) three clinical-stage candidate drugs for oncology, including the core product HX009 and the main products HX301 and HX044; and (ii) seven preclinical-stage candidate drugs, including antibody-drug conjugates, bispecific antibodies, and monoclonal antibodies targeting the autoimmune and oncology markets. During the reporting period, the company also developed HX008, which has been transferred to a biopharmaceutical company specializing in cancer therapy.